Cargando…
Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411284/ https://www.ncbi.nlm.nih.gov/pubmed/31959650 http://dx.doi.org/10.2337/dci19-0067 |
| _version_ | 1783568345040158720 |
|---|---|
| author | Nauck, Michael A. Kreiner, Eskil Rasmussen, Søren Saevereid, Hans A. Buse, John B. |
| author_facet | Nauck, Michael A. Kreiner, Eskil Rasmussen, Søren Saevereid, Hans A. Buse, John B. |
| author_sort | Nauck, Michael A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7411284 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74112842021-02-01 Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 Nauck, Michael A. Kreiner, Eskil Rasmussen, Søren Saevereid, Hans A. Buse, John B. Diabetes Care e-Letters: Comments and Responses American Diabetes Association 2020-02 2020-01-13 /pmc/articles/PMC7411284/ /pubmed/31959650 http://dx.doi.org/10.2337/dci19-0067 Text en © 2020 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. |
| spellingShingle | e-Letters: Comments and Responses Nauck, Michael A. Kreiner, Eskil Rasmussen, Søren Saevereid, Hans A. Buse, John B. Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 |
| title | Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 |
| title_full | Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 |
| title_fullStr | Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 |
| title_full_unstemmed | Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 |
| title_short | Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 |
| title_sort | response to comment on nauck et al. effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the leader randomized trial. diabetes care 2019;42:1912–1920 |
| topic | e-Letters: Comments and Responses |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411284/ https://www.ncbi.nlm.nih.gov/pubmed/31959650 http://dx.doi.org/10.2337/dci19-0067 |
| work_keys_str_mv | AT nauckmichaela responsetocommentonnaucketaleffectsofliraglutidecomparedwithplacebooneventsofacutegallbladderorbiliarydiseaseinpatientswithtype2diabetesathighriskforcardiovasculareventsintheleaderrandomizedtrialdiabetescare20194219121920 AT kreinereskil responsetocommentonnaucketaleffectsofliraglutidecomparedwithplacebooneventsofacutegallbladderorbiliarydiseaseinpatientswithtype2diabetesathighriskforcardiovasculareventsintheleaderrandomizedtrialdiabetescare20194219121920 AT rasmussensøren responsetocommentonnaucketaleffectsofliraglutidecomparedwithplacebooneventsofacutegallbladderorbiliarydiseaseinpatientswithtype2diabetesathighriskforcardiovasculareventsintheleaderrandomizedtrialdiabetescare20194219121920 AT saevereidhansa responsetocommentonnaucketaleffectsofliraglutidecomparedwithplacebooneventsofacutegallbladderorbiliarydiseaseinpatientswithtype2diabetesathighriskforcardiovasculareventsintheleaderrandomizedtrialdiabetescare20194219121920 AT busejohnb responsetocommentonnaucketaleffectsofliraglutidecomparedwithplacebooneventsofacutegallbladderorbiliarydiseaseinpatientswithtype2diabetesathighriskforcardiovasculareventsintheleaderrandomizedtrialdiabetescare20194219121920 |